ACR–ACNM–ARS–SNMMI PRACTICE PARAMETER FOR THE PERFORMANCE OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) THERAPY

PREAMBLE

INTRODUCTION

II.

INDICATIONS

III.

QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNEL

IV.

SPECIFICATIONS OF THE EXAMINATION

IV.

SPECIFICATIONS OF THE EXAMINATION

Pre-Treatment Evaluation

IV.

SPECIFICATIONS OF THE EXAMINATION

Treatment Procedures for Infusion of Lu-177 PSMA

IV.

SPECIFICATIONS OF THE EXAMINATION

Post-Therapy Management

DOCUMENTATION

VI.

EQUIPMENT SPECIFICATIONS

VII.

RADIATION SAFETY IN IMAGING

VIII.

QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION

ACKNOWLEDGEMENTS

Writing Committee – members represent their societies in the initial and final revision of this practice parameter

ACR
Morris, Zachary MD, Co-Chair
Surasi, Devaki Shilpa MD, Co-Chair
Karagulle Kendi, A. Tuba MD
Wong, Terence Z MD, PhD

SNMMI
Calais, Jeremie MD, MSc
Marcus, Charles MD
Savir-Baruch, Bital MD

ARS
Folkert, Michael MD, PhD
Hassanzadeh, Comron MD, MPH

ACNM
Osmany, Saabry MD
Zukotynski, Katherine MD, PhD

Committee on Practice Parameters – Nuclear Medicine and Molecular Imaging

(ACR Committee responsible for sponsoring the draft through the process)

Ghesani, Munir V MD, Chair	Subramaniam, Rathan M MBA, MD, MPH, PhD, Chair	Aboian, Mariam MD, PhD	Akin, Esma A MD
Bartel, Twyla B DO, MBA	Dibble, Elizabeth H MD	Gerard, Perry S MD	Karagulle Kendi, A. Tuba MD
Marcus, Charles MD	Mercier, Gustavo A MD, PhD	Peacock, Justin G MD, PhD	Solnes, Lilja B MBA, MD
Surasi, Devaki Shilpa MD	Trout, Andrew T MD	Wong, Terence Z MD, PhD	Zukotynski, Katherine MD, PhD

Committee on Practice Parameters and Technical Standards

(ACR Committee responsible for sponsoring the draft through the process)

Caplin, Drew M MD, Chair

Committee on Practice Parameters – Radiation Oncology

(ACR Committee responsible for sponsoring the draft through the process)

Schechter, Naomi MD, Chair	Berkowitz, Aviva MD	Chao, Samuel MD	Davis, Brian J MD, PhD
Frank, Steven J MD	Freedman, Laura MD	Garsa, Adam MD	Lo, Simon S. ChB, MB
Morris, Zachary MD	Rabatic, Bryan MD	Reilly, Michael PhD	Saeed, Hina MD
Sio, Terence Tai-Weng MD, MS	Wallner, Paul DO

Larson, David B MBA, MD, Chair, Commission on Quality and Safety

Rohren, Eric MD, PhD, Chair, Commission on Nuclear Medicine & Molecular Imaging

Small, William MD, Chair, Commission on Radiation Oncology

Comments Reconciliation Committee

Moriarity, Andrew MD - CSC, Chair	Rodgers, Daniel MD - CSC, Co-Chair	Bartel, Twyla B DO, MBA	Calais, Jeremie MD, MSc
Caplin, Drew M MD	Chao, Samuel MD	Folkert, Michael MD, PhD	Ghesani, Munir V MD
Hassanzadeh, Comron MD, MPH	Karagulle Kendi, A. Tuba MD	Larson, David B MBA, MD	Marcus, Charles MD
Morris, Zachary MD	Osmany, Saabry MD	Rohren, Eric MD, PhD	Savir-Baruch, Bital MD
Schechter, Naomi MD	Small, William MD	Subramaniam, Rathan M MBA, MD, MPH, PhD	Surasi, Devaki Shilpa MD
Wong, Terence Z MD, PhD	Zukotynski, Katherine MD, PhD

REFERENCES

1. American College of Radiology. ACR-AAPM-ACNM-SNMMI Technical Standard for Therapeutic Procedures Using Radiopharmaceuticals. Available at https://gravitas.acr.org/PPTS/GetDocumentView?docId=153+&releaseId=2
2. Benešová M, Bauder-Wüst U, Schäfer M, et al. Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors. J Med Chem. 2016 Mar 10;59(5):1761-75.
3. Pluvicto, 2022. https://www.novartis.com/us-en/sites/novartis_us/files/pluvicto.pdf.
4. Kurth J, Krause BJ, Schwarzenböck SM, Stegger L, Schäfers M, Rahbar K. External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies. EJNMMI Res. 2018 Apr 12;8(1):32.
5. Schuchardt C, Zhang J, Kulkarni HR, Chen X, Muller D, Baum RP. Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry. Journal of Nuclear Medicine. 63(8):1199-1207, 2022 08.
6. Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine. 385(12):1091-1103, 2021 09 16.
7. Sonbol MB, Halfdanarson TR, Hilal T. Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review. JAMA Oncol. 2020 Jul 01;6(7):1086-1092.
8. Pritzl SL, Kusne Y, Halfdanarson TR, et al. Spectrum of therapy-related clonal cytopenias and neoplasms after exposure to Lutetium-177-Dotatate. Leuk Res. 2024 Jan;136():S0145-2126(23)00699-9.
9. Muniz M, Loprinzi CL, Orme JJ, et al. Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going. Cancer Treat Rev. 2024 Jun;127():S0305-7372(24)00076-8.
10. American College of Radiology. ACR-AAPM radiation safety officer resources. Available at: https://www.acr.org/-/media/ACR/Files/Radiology-Safety/Radiation-Safety/ACRAAPM-RSO-Resources.pdf?la=en. .
11. American College of Radiology. ACR-ARS Practice Parameter for Radiation Oncology. Available at https://gravitas.acr.org/PPTS/GetDocumentView?docId=200+&releaseId=2
12. Scher HI, Morris MJ, Stadler WM, et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 Apr 20;34(12):1402-18.
13. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res. 2009 Jun;15(2):167-72.
14. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998 Oct;52(4):637-40.
15. Fendler WP, Eiber M, Beheshti M, et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1466-1486.
16. Rosar F, Burgard C, David S, et al. Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT. Sci Rep. 2024 May 17;14(1):11271.
17. Kratochwil C, Fendler WP, Eiber M, et al. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). European Journal of Nuclear Medicine & Molecular Imaging. 50(9):2830-2845, 2023 07.
18. American College of Radiology. ACR-ARS Practice Parameter on Informed Consent- Radiation Oncology. Available at https://gravitas.acr.org/PPTS/GetDocumentView?docId=141+&releaseId=2
19. NRC, 2011. https://www.nrc.gov/docs/ML1036/ML103620153.pdf.
20. NRC, 2018. https://www.nrc.gov/docs/ML1813/ML18136A824.pdf.
21. NCRP, 2015. https://ncrponline.org/publications/reports/ncrp-reports-155/.
22. Zoberi JE, Garcia-Ramirez J, Luechtefeld D, et al. Logistical, technical, and radiation safety aspects of establishing a radiopharmaceutical therapy program: A case in Lutetium-177 prostate-specific membrane antigen (PSMA) therapy. Journal of Applied Clinical Medical Physics. 24(4):e13899, 2023 Apr.
23. Graves SA. Radiation Safety Considerations of Household Waste Disposal After Release of Patients Who Have Received [177Lu]Lu-PSMA-617. Journal of Nuclear Medicine. 64(10):1567-1569, 2023 10.
24. https://www.usp.org/small-molecules/general-chapter-825.
25. https://www.novartis.com/us-en/sites/novartis_us/files/pluvicto.pdf.
26. Jeffers CD, Lawhn-Heath C, Butterfield RI, Hoffman JM, Scott PJH. SNMMI Clinical Trials Network Research Series for Technologists: Clinical Research Primer- Use of Imaging Agents in Therapeutic Drug Development and Approval. J Nucl Med Technol. 2022 Jun 14;():jnmt.122.264372.
27. Swiha M, Gafita A, Nguyen A, Emmett L. Treatment Response Imaging in Prostate Cancer. PET Clin. 2024 Jul;19(3):S1556-8598(24)00024-5.
28. Peters SMB, Mink MCT, Privé BM, et al. Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation. EJNMMI Res. 2023 Jan 24;13(1):6.
29. Pepin A, Lee V, O'Brien S, Mulugeta P, Taunk NK. Management of Dry Eye Toxicity After Treatment With 177Lu-PSMA-617 Radioligand Therapy. Pract Radiat Oncol. 2024;14(4):S1879-8500(24)00079-1.
30. American College of Radiology. ACR Practice Parameter for Communication of Diagnostic Imaging Findings. Available at https://gravitas.acr.org/PPTS/GetDocumentView?docId=74+&releaseId=2
31. American College of Radiology. ACR–AAPM Technical Standard for Nuclear Medical Physics Performance Monitoring of Gamma Cameras. Available at https://gravitas.acr.org/PPTS/GetDocumentView?docId=196+&releaseId=2

Appendix A